TrialScientific reports2022

Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial.

Inês Bernardino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.